CELLINK has published Annual Report 2019/2020 for the financial year which covers September 1, 2019 to December 31, 2020. The Annual Report is available on CELLINK’s website: www.cellink.com/investors. The printed version of Annual Report 2019/2020 will be available during calendar week 13.
For more information, please contact:
Isabelle Ljunggren, Head of Communications CELLINK
Phone: +46 708-30 08 90
This is information that CELLINK is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 16:50 CET on March 17, 2021.
Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,600 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com/investors